Ilumya®

Understanding Ilumya® 

Ilumya® (tildrakizumab-asmn) is a monoclonal antibody therapy that targets interleukin-23 (IL-23), a key cytokine involved in inflammatory and autoimmune diseases. It is used to treat moderate-to-severe plaque psoriasis by reducing skin inflammation and slowing excessive skin cell growth. Ilumya® helps improve skin clearance and reduces the severity of psoriasis symptoms with long-lasting effects.

How Ilumya® Works:

• Targets IL-23 to reduce inflammation in plaque psoriasis.
• Slows excessive skin cell growth, leading to clearer skin.
• Provides long-lasting relief with a maintenance dosing schedule.

FDA Approval:

• March 21, 2018 – Approved for the treatment of moderate-to-severe plaque psoriasis

For more information, please visit the Ilumya® patient website and speak with your healthcare provider to determine if Ilumya® is the right treatment option for you.